Catalog Home Page

Nucleobase-modified antisense oligonucleotides containing 5-(phenyltriazol)-2′-deoxyuridine nucleotides induce exon-skipping in vitro

Le, B.T., Hornum, M., Sharma, P.K., Nielsen, P. and Veedu, R.N. (2017) Nucleobase-modified antisense oligonucleotides containing 5-(phenyltriazol)-2′-deoxyuridine nucleotides induce exon-skipping in vitro. RSC Advances, 7 (86). pp. 54542-54545.

[img]
Preview
PDF - Published Version
Download (436kB) | Preview
Free to read: https://doi.org/10.1039/C7RA10964D
*No subscription required

Abstract

Chemically-modified antisense oligonucleotide-mediated exon-skipping has been validated as a therapeutic strategy for tackling several disease pathologies, particularly duchenne muscular dystrophy. To date, only sugar-modified and internucleotide linkage-modified oligonucleotide chemistries have been explored for exon-skipping applications. Herein, for the first time, we have investigated the potential of nucleobase-modified antisense oligonucleotides to induce exon-skipping. For this purpose, we have synthesised 5-(phenyltriazol)-2′-deoxyuridine-modified 2′-O-methyl mixmer antisense oligonucleotides, and evaluated their efficacy to induce exon-23 skipping in H-2Kb-tsA58 (H2K) mdx mouse myotubes as a model system. Our results showed that the phenyltriazol base-modified AOs successfully induced efficient exon-skipping in a DMD transcript. Our findings open up the exploration of novel base-modified antisense oligonucleotides for exon-skipping applications.

Publication Type: Journal Article
Murdoch Affiliation: Centre for Comparative Genomics
Publisher: Royal Society of Chemistry
Copyright: © 2017 Royal Society of Chemistry
URI: http://researchrepository.murdoch.edu.au/id/eprint/39894
Item Control Page Item Control Page

Downloads

Downloads per month over past year